Rethinking Clinical Trials

MARCH 6, 2024

Lab results for HbA1c, cholesterol, triglycerides, blood pressure, weight were taken at 0, 6 and 12 months. There were also surveys to assess program education, diet, a self-efficacy questionnaire, and a self-assessed physical and mental health questionnaire at 0, 6, and 12 months. The treatment group started with a mean 10.3

Clinical Trials 141

Clinical Trials Clinical Trials Medicine Trials 141

Rethinking Clinical Trials

SEPTEMBER 28, 2023

Our partners want to know the data and what it takes to collect it in a rigorous way. Tags #pctGR, @Collaboratory1 The post Grand Rounds September 22, 2023: Integrating Community Health Workers into Team-Based, Early Childhood Preventative Care (Tumaini Rucker Coker, MD, MBA) appeared first on Rethinking Clinical Trials.

Trials 269

Trials Clinical Trials Clinical Trials Research 269

Rethinking Clinical Trials

MARCH 1, 2023

To reduce the burden on sites, the study has simplified data reporting by reducing time points data, reducing the number of forms that need to be submitted, and reducing the number of data elements within a form. The study does not include tissue specimen collection, image submission, or patient-reported outcome instruments.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Packaging 130

Pharmaceutical Technology

APRIL 13, 2023

Although the findings in the report are only preliminary, they shed light at the considerations behind the high price tags of gene therapies. Sickle cell disease is an inherited blood disorder that is caused by mutations in the HBB gene, which codes for the oxygen-carrying protein haemoglobin in red blood cells.

Gene Therapy 147

Gene Therapy Gene FDA Approval Licensing 147

pharmaphorum

JUNE 12, 2022

bluebird bio started last week on tenterhooks, as FDA advisors cast their eyes over data for two gene therapy candidates that are key to its future as a commercially viable concern. Beti-cel has already been approved for marketing in Europe as Zynteglo, with a price tag of around $1.8

Gene Therapy 57

Gene Therapy Gene Marketing Trials 57

XTalks

JUNE 8, 2021

In addition, recent data from a Phase I trial has shown ‘remarkable’ long-term results of the gene therapy in children with the disease. With a price tag of over $2.5 There are four main types of SMA — type 0 to IV — with type I being the most common and severe form of the disease. Zolgensma Gene Therapy: START Trial.

Gene Therapy 110

Gene Therapy Gene Protein Trials 110